Pharmacology of Proteinopathies

This feed focuses on the pharmacology of proteinopathies - diseases in which proteins abnormally aggregate (i.e. Alzheimer’s, Parkinson’s, etc.). Discover the latest research in this field with this feed.

July 6, 2019

An Animal Model to Test Reversal of Cognitive Decline Associated with Beta-Amyloid Pathologies

Methods in Molecular Biology
Farah DebaAyman K Hamouda
September 10, 2020
Review
Open Access

Proteostasis and Proteotoxicity in the Network Medicine Era

International Journal of Molecular Sciences
Marta LualdiMauro Fasano
May 9, 2020
Open Access

Transmission of ALS pathogenesis by the cerebrospinal fluid

Acta Neuropathologica Communications
Pooja Shree MishraJean-Pierre Julien
November 22, 2018
Open Access

Neuromuscular junction abnormalities in a zebrafish loss-of-function model of TDP-43

Journal of Neurophysiology
Poulomee BosePierre Drapeau
November 3, 2020
Open Access

Ofloxacin as a Disruptor of Actin Aggresome "Hirano Bodies": A Potential Repurposed Drug for the Treatment of Neurodegenerative Diseases

Frontiers in Aging Neuroscience
Samridhi PathakAvinash Kale
December 19, 2017
Review

Features and outcomes of drugs for combination therapy as multi-targets strategy to combat Alzheimer's disease

Journal of Ethnopharmacology
Atish Kumar SahooSatish Kanhar
November 4, 2019
Open Access

TDP-43 inhibitory peptide alleviates neurodegeneration and memory loss in an APP transgenic mouse model for Alzheimer's disease

Biochimica Et Biophysica Acta. Molecular Basis of Disease
Ju GaoXinglong Wang
December 7, 2018
Review
Open Access

Modeling Parkinson's Disease and Atypical Parkinsonian Syndromes Using Induced Pluripotent Stem Cells

International Journal of Molecular Sciences
Takayasu MishimaYoshio Tsuboi
December 10, 2017
Review

Dementia with Lewy bodies and Parkinson's disease-dementia: current concepts and controversies

Journal of Neural Transmission
Kurt A Jellinger
November 2, 2019
Open Access

Myelin Pathology: Involvement of Molecular Chaperones and the Promise of Chaperonotherapy

Brain Sciences
Federica ScaliaFrancesco Cappello
November 4, 2020

Targeting nuclear protein TDP-43 by cell division cycle kinase 7 inhibitors: A new therapeutic approach for amyotrophic lateral sclerosis

European Journal of Medicinal Chemistry
Elisa Rojas-PratsAna Martinez
October 9, 2019
Open Access

Cofilin, a Master Node Regulating Cytoskeletal Pathogenesis in Alzheimer's Disease

Journal of Alzheimer's Disease : JAD
David E Kang, Jung A Woo
August 9, 2020
Open Access

A chemical genomics-aggrephagy integrated method studying functional analysis of autophagy inducers

Autophagy
Tetsushi KatauraMasaya Imoto
November 30, 2018
Review
Open Access

Renewed assessment of the risk of emergent advanced cell therapies to transmit neuroproteinopathies

Acta Neuropathologica
Paul A De SousaMark W Head
May 6, 2019
Open Access

A mutant MATR3 mouse model to explain multisystem proteinopathy

The Journal of Pathology
Xiao ZhangYukio Ando

Sign up to follow this feed and discover related papers.

Related Feeds

3D Cellular Models of Brain and Neurodegeneration

Brain organoids are three-dimensional in vitro cellular models of the brain that can recapitulate many processes such as the neurodevelopment. In addition, these organoids can be combined with other cell types, such as neurons and astrocytes to study their interactions in assembloids. Disease processes can also be modeled by induced pluripotent stem cell-derived organoids and assembloids from patients with neurodegenerative disorders. Discover the latest research on the models here.

ALS & FTD: TDP-43

TAR DNA-binding protein 43 (TDP-43) is a pathological protein identified in sporadic Amyotrophic Lateral Sclerosis (ALS) and Frontotemporal Dementia (FTD). Here are the latest discoveries pertaining to TDP-43 and these diseases.

ALS: Genetics

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disorder characterized by muscle weakness. ALS is a genetically heterogeneous disorder with several causative genes. Here are the latest discoveries pertaining to the genetics of this disease.

ALS: Pathogenic Mechanisms

Amyotrophic Lateral Sclerosis is a progressive neurodegenerative disorder characterized by muscle weakness. Here is the latest research investigating pathogenic mechanisms that underlie this genetically heterogeneous disorder.

ALS: Phenotypes

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disorder characterized phenotypically by progressive muscle weakness. Clinical phenotypes of ALS can be classified based on the pattern, level, and area of onset (e.g. bulbar, cervical, lumbar). Here is the latest research investigating phenotypes of ALS.

ALS: Prions

Prions are misfolded proteins which characterize several fatal neurodegenerative diseases. Prion-like mechanisms are associated with the pathogenesis of Amyotrophic Lateral Sclerosis (ALS). Here is the latest research on ALS and prions.

ALS: Stress Granules

Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease characterized by cytoplasmic protein aggregates within motor neurons. TDP-43 is an ALS-linked protein that is known to regulate splicing and storage of specific mRNAs into stress granules, which have been implicated in formation of ALS protein aggregates. Here is the latest research in this field.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.

Age-related Dementia

Dementias are a group of conditions, including Alzheimer's disease, vascular dementia, and frontotemporal dementia, characterized by deficiencies in cognitive abilities. Age-related dementia refers to dementias that occur in older individuals, usually 60+ years old, in contrast to early-onset dementia. Follow the latest research on age-related dementia here.

Alexander Disease

Alexander disease is a rare leukodystrophy caused by mutations in the astrocyte-specific intermediate filament protein glial fibrillary acidic protein (GFAP). Here is the latest research on this disease.

© 2021 Meta ULC. All rights reserved
/feed-previews/pharmacology-of-proteinopathies/9bd82140-cea7-408e-9bc5-3b147d353819